Review paper
Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection
Abstract
Context: Quantitative hepatitis B surface antigen (qHBsAg) levels have been shown to assist the management of patients with chronic hepatitis B virus (HBV) infection and reflect the level of transcriptional activity of covalently closed circular DNA (cccDNA). It has been indicated the importance of co-operative use of qHBsAg and HBV-DNA for diagnosis and monitoring of CHB treatment. Evidence Acquisition: In order to achieve a comprehensive...
Paper Details
Title
Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection
Published Date
Mar 8, 2017
Journal
Volume
17
Issue
4
References66
Original paper
# 1Julie Lucifora(TUM: Technical University of Munich)
30
# 2Yuchen Xia(TUM: Technical University of Munich)
26
Last. Ulrike Protzer(TUM: Technical University of Munich)
65
Current antiviral agents can control but not eliminate hepatitis B virus (HBV), because HBV establishes a stable nuclear covalently closed circular DNA (cccDNA). Interferon-α treatment can clear HBV but is limited by systemic side effects. We describe how interferon-α can induce specific degradation of the nuclear viral DNA without hepatotoxicity and propose lymphotoxin-β receptor activation as a therapeutic alternative. Interferon-α and lymphotoxin-β receptor activation up-regulated APOBEC3A an...
Review paper
# 1Tai‐Chung Tseng(Buddhist Tzu Chi General Hospital)
37
# 2Chun‐Jen Liu(NTUH: National Taiwan University Hospital)
66
Last. Jia‐Horng Kao(NTUH: National Taiwan University Hospital)
85
Background & AimsPatients with chronic hepatitis B virus (HBV) infection have a high risk for developing hepatocellular carcinoma (HCC). Patients with lower levels of hepatitis B surface antigen (HBsAg) have higher chances of losing HBsAg than those with high levels. However, little is known about whether higher levels of HBsAg increase risk for HCC.MethodsWe followed 2688 Taiwanese HBsAg-positive patients without evidence of cirrhosis for a mean time period of 14.7 years. In addition to the kno...
Original paper
# 1Maurizia Rossana Brunetto(Azienda Ospedaliera Universitaria Pisana)
64
# 2F. Moriconi(Azienda Ospedaliera Universitaria Pisana)
10
Last. Stephanos J. Hadziyannis(Henry Dunant Hospital)
57
We investigated the relationship between hepatitis B virus surface antigen (HBsAg) serum level decline and posttreatment response in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B from a large multinational study of pegylated interferon alfa-2a (peginterferon alfa-2a), with or without lamivudine, versus lamivudine alone. Serum HBsAg was quantified using the Architect assay (Abbott Diagnostics) at pretreatment, end of treatment (week 48), and 6 months after the end of tr...
Original paper
# 1E. Jenny Heathcote(University of Toronto)
45
# 2Patrick Marcellin(Hôpital Beaujon)
115
Last. Franck Rousseau(Gilead Sciences (United States))
41
Original paper
# 1Rami Moucari(Hôpital Beaujon)
27
# 2Vincent Mackiewicz(Hôpital Beaujon)
14
Last. Patrick Marcellin(Hôpital Beaujon)
115
Pegylated interferon alfa-2a (PEG-IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on-treatment serum HBsAg kinetics to predict SVR in HBeAg-negative patients treated with PEG-IFN. Forty-eight consecutive patients were treated with ...
Original paper
# 1Alexander J. Thompson(St Vincent's Hospital)
46
# 2Tin Nguyen(St Vincent's Hospital)
14
Last. Stephen Locarnini(VIDRL: Victorian Infectious Diseases Reference Laboratory)
76
Although threshold levels for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) titers have recently been proposed to guide therapy for chronic hepatitis B (CHB), their relationship to circulating hepatitis B virus (HBV) DNA and intrahepatic HBV replicative intermediates, and the significance of emerging viral variants, remains unclear. We therefore tested the hypothesis that HBsAg and HBeAg titers may vary independently of viral replication in vivo . In all, 149 treatment-na...
Original paper
# 1Jerzy Jaroszewicz(Medical University of Białystok)
32
# 2Beatriz Calle Serrano(MHH: Medizinische Hochschule Hannover)
8
Last. Markus Cornberg(MHH: Medizinische Hochschule Hannover)
71
Background & Aims The quantifiable level of HBsAg has been suggested as a predictor of treatment response in chronic hepatitis B. However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients. Methods 226 HBV-monoinfected patients, not undergoing antiviral therapy, were analyzed in a cross-sectional study. Patients were categoriz...
Original paper
# 1Maurizia Rossana Brunetto(Azienda Ospedaliera Universitaria Pisana)
64
# 2Filippo Oliveri(Azienda Ospedaliera Universitaria Pisana)
33
Last. Ferruccio Bonino(UniPi: University of Pisa)
59
Original paper
# 1Tin Nguyen(St Vincent's Hospital)
14
# 2Alexander J. Thompson(St Vincent's Hospital)
46
Last. Stephen Locarnini(VIDRL: Victorian Infectious Diseases Reference Laboratory)
76
Background & Aims Data from clinical trials suggest a potential role for on-treatment monitoring of serum HBsAg titres during interferon-alpha (pegIFN) therapy in predicting virological responses. However, baseline HBsAg titres during the natural history of chronic hepatitis B (CHB) have not been well-characterized. We aimed to define the serum HBsAg titres during the different phases of CHB in a cohort of Asian patients infected with either genotype B or C HBV. Methods Two-hundred and twenty pa...
Original paper
# 1Henry Lik‐Yuen Chan(CUHK: Chinese University of Hong Kong)
101
# 2Vincent Wai‐Sun Wong(CUHK: Chinese University of Hong Kong)
126
Last. Joseph J.�Y. Sung(CUHK: Chinese University of Hong Kong)
149
Serum hepatitis B surface antigen (HBsAg) quantification has been suggested to reflect the concentration of covalently closed circular DNA in the liver. We aimed to investigate the HBsAg levels at different stages of chronic hepatitis B and the changes in HBsAg level during the natural progression of disease. One hundred seventeen untreated patients with chronic hepatitis B were studied with longitudinal follow-up for 99 ± 16 months. HBsAg quantification was performed at the first visit, the las...
1
2
3
4
5
6
7